CONTEXT: Although numerous studies of the efficacy of exercise are reported, few studies have evaluated changes in characteristics of exercise dose in women with cancer both during and after cancer treatment. OBJECTIVES: To describe the characteristics of exercise dose (i.e., frequency, duration, and intensity) and evaluate for differences in symptom severity (i.e., fatigue, sleep disturbance, depression, and pain) between women who did and did not exercise during and after cancer treatment. METHODS: In a sample of 119 women, two groups were classified: exercisers and nonexercisers. Exercisers were defined as women who met specific criteria for frequency (three times per week), duration (20 minutes/session), intensity (moderate), and mode (aerobic). Nonexercisers were defined as women who did not meet all these criteria. Evaluation of exercise dose was completed at baseline (T1: the week before chemotherapy cycle 2), at the end of cancer treatment (T2), and at the end of the study (T3: approximately one year after the T1 assessment) using self-report exercise questionnaires. RESULTS: Approximately 50% of the participants exercised during treatment and 70% exercised after treatment. At T1, exercisers had lower total fatigue, lower behavioral and sensory subscale fatigue scores, and lower depression scores (P = 0.038) than nonexercisers. No significant differences in sleep disturbance or pain were found between groups. At T2, exercisers had lower cognitive/mood subscale fatigue and depression scores than nonexercisers (P = 0.047). At T3, no significant differences were found between groups in any symptom severity scores. CONCLUSION: Both during and after cancer treatment, achieving or maintaining exercise guideline levels were met by most patients. Further study is needed to examine the link between exercise dose and symptom severity.
RCT Entities:
CONTEXT: Although numerous studies of the efficacy of exercise are reported, few studies have evaluated changes in characteristics of exercise dose in women with cancer both during and after cancer treatment. OBJECTIVES: To describe the characteristics of exercise dose (i.e., frequency, duration, and intensity) and evaluate for differences in symptom severity (i.e., fatigue, sleep disturbance, depression, and pain) between women who did and did not exercise during and after cancer treatment. METHODS: In a sample of 119 women, two groups were classified: exercisers and nonexercisers. Exercisers were defined as women who met specific criteria for frequency (three times per week), duration (20 minutes/session), intensity (moderate), and mode (aerobic). Nonexercisers were defined as women who did not meet all these criteria. Evaluation of exercise dose was completed at baseline (T1: the week before chemotherapy cycle 2), at the end of cancer treatment (T2), and at the end of the study (T3: approximately one year after the T1 assessment) using self-report exercise questionnaires. RESULTS: Approximately 50% of the participants exercised during treatment and 70% exercised after treatment. At T1, exercisers had lower total fatigue, lower behavioral and sensory subscale fatigue scores, and lower depression scores (P = 0.038) than nonexercisers. No significant differences in sleep disturbance or pain were found between groups. At T2, exercisers had lower cognitive/mood subscale fatigue and depression scores than nonexercisers (P = 0.047). At T3, no significant differences were found between groups in any symptom severity scores. CONCLUSION: Both during and after cancer treatment, achieving or maintaining exercise guideline levels were met by most patients. Further study is needed to examine the link between exercise dose and symptom severity.
Authors: M L Segar; V L Katch; R S Roth; A W Garcia; T I Portner; S G Glickman; S Haslanger; E G Wilkins Journal: Oncol Nurs Forum Date: 1998 Jan-Feb Impact factor: 2.172
Authors: Bernardine M Pinto; Georita M Frierson; Carolyn Rabin; Joseph J Trunzo; Bess H Marcus Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: V Mock; K H Dow; C J Meares; P M Grimm; J A Dienemann; M E Haisfield-Wolfe; W Quitasol; S Mitchell; A Chakravarthy; I Gage Journal: Oncol Nurs Forum Date: 1997-07 Impact factor: 2.172
Authors: Victoria Mock; Constantine Frangakis; Nancy E Davidson; Mary E Ropka; Mary Pickett; Barbara Poniatowski; Kerry J Stewart; Lane Cameron; Kristin Zawacki; Laura J Podewils; Gary Cohen; Ruth McCorkle Journal: Psychooncology Date: 2005-06 Impact factor: 3.894
Authors: Karen L Syrjala; Mark P Jensen; M Elena Mendoza; Jean C Yi; Hannah M Fisher; Francis J Keefe Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Jennifer A Wenzel; Kathleen A Griffith; Jingjing Shang; Carol B Thompson; Haley Hedlin; Kerry J Stewart; Theodore DeWeese; Victoria Mock Journal: Oncologist Date: 2013-04-08
Authors: Theresa Coles; Antonia V Bennett; Xianming Tan; Claudio L Battaglini; Hanna K Sanoff; Ethan Basch; Roxanne E Jensen; Bryce B Reeve Journal: Support Care Cancer Date: 2018-02-22 Impact factor: 3.603
Authors: Brenda Cartmel; Meghan Hughes; Elizabeth A Ercolano; Linda Gottlieb; Fangyong Li; Yang Zhou; Maura Harrigan; Jennifer A Ligibel; Vivian E von Gruenigen; Radhika Gogoi; Peter E Schwartz; Harvey A Risch; Lingeng Lu; Melinda L Irwin Journal: Gynecol Oncol Date: 2021-03-26 Impact factor: 5.482
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452
Authors: Bernard Favrat; Katharina Balck; Christian Breymann; Michael Hedenus; Thomas Keller; Anna Mezzacasa; Christoph Gasche Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240